Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.
Dr. John Cush RheumNow
1 year 2 months ago
Lancet viewpoint on early imaging in axial SpA. Over-reliance on BM edema = incr in misDx. Newer tech (high-res sequences, quantitative MRI, radiomics, artificial intelligence) may improve Dx precision. Remember the SI is susceptible to mechanical stress https://t.co/E80GyQGIM0 https://t.co/egIhNP17pQ
Dr. John Cush RheumNow
1 year 2 months ago
Early RA or undiff. arthritis (UA) shows initial hi-dose steroids have significantly better earlier outcomes, but lower doses have fewer early side effects. IMPROVED used high dose GC (60 mg/d tapered to 7.5 mg in 7wks). tREACH used lower dose GC (15 mg/d tapered in 10 wks to https://t.co/TkrGPb6EBZ
Dr. John Cush RheumNow
1 year 2 months ago
JAMA CME review of Immune Thrombotic Thrombocytopenic Purpura (iTTP) - thrombotic microangiopathy w/ hemolytic anemia (MAHA) & thrombocytopenia. iTTP incidence is 2-6 per million. Caused by Abs to ADAMTS13), w/ low ADAMTS13 activity vWF multimers bind platelets https://t.co/bvCexDPBmq
Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.
Dr. John Cush RheumNow
1 year 2 months ago
Annals of Internal Medicine has published a CME review of LYME DISEASE. Most Lyme is Dx by onset of the erythema migrans rashes,. Lyme Ab testing is of low sensitivity at onset but more sensitive w/ time & CNS, CV complications. or Mono- or oligoarticular arthritis https://t.co/FMwQgcadik
Dr. John Cush RheumNow
1 year 2 months ago
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/i5Q5UfE9v3
Dr. John Cush RheumNow
1 year 2 months ago
How Living With Childhood-Onset Lupus Impacts Mental Health
Children, teens, and young adults with childhood-onset systemic lupus erythematosus (cSLE) require intense immunosuppressive treatments to prevent organ damage. Recently, the mental health burden for cSLE patients has https://t.co/JXkdYiAO9o
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA) were initially developed as glucose-lowering agents for the treatment of Type 2 Diabetes. Since their introduction, they have been noted to have a myriad of other benefits, including cardiovascular and renal protective effects in patients both with and without diabetes. Here, we will review the evidence for SGLT2i and GLP1-RA in lupus.
Dr. John Cush RheumNow
1 year 2 months ago
Emulation Trials in SLE: Real or Fake
Dr. Janet Pope, Ontario, Canada, discusses emulation trials in systemic lupus erythematosus.
https://t.co/wVmMfLVAuQ https://t.co/V4VGVncSE9
Dr. John Cush RheumNow
1 year 2 months ago
2024 ACR Lupus Nephritis Guidelines: The Controversies
Drs. Maria Dall’Era & Michelle Petri discuss the sticking points in the latest lupus nephritis recommendations.
🗣️ Insightful, honest, and essential for your practice.
📍Full update on RheumNow: https://t.co/KPjyCrMTBr https://t.co/VoOslSqs99
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose?
